Immatics Consolidated Income Trend from 2010 to 2022

IMTX -  USA Stock  

USD 7.06  0.45  6.81%

Immatics Consolidated Income yearly trend continues to be fairly stable with very little volatility. Consolidated Income will likely drop to -100,703,553 in 2022. . Immatics Interest Expense is fairly stable at the moment as compared to the past year. Immatics reported Interest Expense of 1.73 Million in 2021. Net Income to Non Controlling Interests is likely to rise to about 598.4 K in 2022, whereas Consolidated Income is likely to drop (100.7 M) in 2022.
  
Refresh
Check Immatics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics main balance sheet or income statement drivers, such as Gross Profit of 31.1 M, Interest Expense of 2.7 M or Net Income to Non Controlling Interests of 598.4 K, as well as many exotic indicators such as Asset Turnover of 0.18, Book Value per Share of 0.41 or Current Ratio of 1.74. Immatics financial statements analysis is a perfect complement when working with Immatics Valuation or Volatility modules. It can also supplement various Immatics Technical models. Please see the analysis of Immatics Correlation against competitors.

Immatics Quarterly Consolidated Income

(16.79 Million)

Share

Immatics Consolidated Income Breakdown

Showing smoothed Consolidated Income of Immatics NV with missing and latest data points interpolated. The portion of profit or loss for the period; net of income taxes; which is attributable to the consolidated entity; before the deduction of Net Income to Non Controlling Interests.Immatics' Consolidated Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immatics' overall financial position and show how it may be relating to other accounts over time.
Consolidated Income10 Years Trend
Decreasing
Slightly volatile
 Consolidated Income 
Share
      Timeline 

Immatics Consolidated Income Regression Statistics

Arithmetic Mean(56,120,119)
Coefficient Of Variation(93.82)
Mean Deviation 36,541,415
Median(32,355,000)
Standard Deviation 52,649,133
Range 179,486,000
R-Value(0.58)
R-Squared 0.34
Significance 0.036691
Slope(7,875,447)

Immatics Consolidated Income History

2019-32.5 M
2020-211.8 M
2021-93.3 M
2022-100.7 M

About Immatics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immatics income statement, its balance sheet, and the statement of cash flows. Immatics investors use historical funamental indicators, such as Immatics's Consolidated Income, to determine how well the company is positioned to perform in the future. Although Immatics investors may use each financial statement separately, they are all related. The changes in Immatics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immatics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immatics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immatics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Consolidated Income-93.3 M-100.7 M
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 188 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immatics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immatics NV using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Immatics Correlation against competitors. Note that the Immatics NV information on this page should be used as a complementary analysis to other Immatics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Immatics Stock analysis

When running Immatics NV price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Is Immatics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immatics NV is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics' value that differs from its market value or its book value, called intrinsic value, which is Immatics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics' market value can be influenced by many factors that don't directly affect Immatics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immatics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.